Superseded · version 1: Pemvidutide^↗

Related names recorded in this version: ALT-801^↗

A glucagon/GLP-1 receptor agonist candidate with trial-registry records.^↗

This is preserved historical wording.
It is no longer the current profile. Read the current profile and its correction notice.

What this version reported

ClinicalTrials.gov lists Altimmune's IMPACT study as completed, last updated May 18, 2026.^↗

Organizations named in cited records:

Trial records: NCT05989711